EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres.
ジャーナル・号・ページ	J. Med. Chem., Vol. 57, Page 2963-2988, Year 2014
掲載日	2014年1月8日 (構造データの登録日)
著者	Gonzalez, A.Z. / Li, Z. / Beck, H.P. / Canon, J. / Chen, A. / Chow, D. / Duquette, J. / Eksterowicz, J. / Fox, B.M. / Fu, J. ...Gonzalez, A.Z. / Li, Z. / Beck, H.P. / Canon, J. / Chen, A. / Chow, D. / Duquette, J. / Eksterowicz, J. / Fox, B.M. / Fu, J. / Huang, X. / Houze, J. / Jin, L. / Li, Y. / Ling, Y. / Lo, M.C. / Long, A.M. / McGee, L.R. / McIntosh, J. / Oliner, J.D. / Osgood, T. / Rew, Y. / Saiki, A.Y. / Shaffer, P. / Wortman, S. / Yakowec, P. / Yan, X. / Ye, Q. / Yu, D. / Zhao, X. / Zhou, J. / Olson, S.H. / Sun, D. / Medina, J.C.
リンク	J. Med. Chem. / PubMed:24601644
手法	X線回折
解像度	1.377 - 2.2006 Å
構造データ	PDB-4occ: co-crystal structure of MDM2(17-111) in complex with compound 48 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-4ode: Co-Crystal Structure of MDM2 with Inhibitor Compound 4 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-4odf: Co-Crystal Structure of MDM2 with Inhibitor Compound 47 手法: X-RAY DIFFRACTION / 解像度: 2.2006 Å PDB-4ogn: Co-Crystal Structure of MDM2 with Inhbitor Compound 3 手法: X-RAY DIFFRACTION / 解像度: 1.377 Å PDB-4ogt: Co-Crystal Structure of MDM2 with Inhbitor Compound 46 手法: X-RAY DIFFRACTION / 解像度: 1.5361 Å PDB-4ogv: Co-Crystal Structure of MDM2 with Inhibitor Compound 49 手法: X-RAY DIFFRACTION / 解像度: 2.197 Å
化合物	ChemComp-2TZ: [(2R,5R,6R)-4-[(2S)-1-(tert-butylsulfonyl)butan-2-yl]-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl]acetic acid ChemComp-HOH: WATER / 水 ChemComp-2U0: (2-{[(3R,5R,6S)-1-[(1S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl]-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]methyl}-1,3-thiazol-5-yl)acetic acid / AM-6761 ChemComp-SO4: SULFATE ION / 硫酸ジアニオン / 硫酸塩 ChemComp-2U1: 6-{[(2S,5R,6R)-4-[(1S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl]-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl]methyl}pyridine-3-carboxylic acid ChemComp-2U5: 6-{[(3R,5R,6S)-1-[(1S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl]-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]methyl}pyridine-3-carboxylic acid ChemComp-2U6: 6-{[(2R,5R,6R)-4-[(1S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl]-6-(3-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-3-oxomorpholin-2-yl]methyl}pyridine-3-carboxylic acid ChemComp-2U7: [(2S,5R,6R)-4-[(2S)-1-(tert-butylsulfonyl)butan-2-yl]-6-(3-chlorophenyl)-5-(4-chlorophenyl)-3-oxomorpholin-2-yl]acetic acid
由来	homo sapiens (ヒト)
キーワード	ligase/ligase inhibitor / MDM2 (Mdm2) / p53 (P53遺伝子) / protein-protein interaction (タンパク質間相互作用) / inhibitor (酵素阻害剤) / ligase-ligase inhibitor complex